Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex interaction study with enoxaparin or unfractionated heparin in healthy male volunteers
NL-OMON36201Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2011
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial in neuromuscular block (NMB) and venous thromboembolism (VTE) comparing Part 1: Bridion + enoxaparin crossover with Part 2: Bridion + unfractionated heparin crossover (2 arms). Primary endpoints: Effect of sugammadex on enoxaparin anti-Xa activity and Effect of sugammadex on UFH APTT activity. Started Sep 2011; status: active, not recruiting.
02
Drugs
Sugammadexenoxaparinheparin
03
Conditions
neuromuscular block (NMB)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON36201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36201.